美國

證券交易委員會

華盛頓特區 20549

 

表單 10-Q

 

根據1934年證券交易法第13或15(d)條款提交的季度報告

 

截至季度的時間2024年9月30日

 

 

根據《1934年證券交易法》第13或15(d)條的過渡報告

 

從 __________ 到 __________ 的過渡期

 

委員會檔案編號001-40535

 

UPEXI公司

(註冊人名稱如章程中所列)

 

內華達

 

83-3378978

(州或其他管轄區的

 公司或組織)

 

(IRS僱主)

識別號)

 

3030北洛點子驅動

坦帕, 佛羅里達

 

33607

(主要執行辦公室地址)

 

(Zip Code)

 

(701353-5425

(註冊人電話號碼,包括區號)

 

____________________________________________________________

(若自上次報告以來更改,前名稱、前地址和前財年)

 

根據該法第12(b)條註冊的證券:

 

每個類別的標題

交易標的

註冊的每個交易所的名稱

普通股,面值 $0.001

UPXI

納斯達克 股票市場有限責任公司

 

請勾選以表明註冊人是否在過去12個月(或在註冊人需提交該報告的較短期間)內根據1934年證券交易法第13條或第15(d)節提交了所有報告,並且在過去90天內是否一直受到此類提交要求的限制。☒     ☐ 不

 

請勾選登記人是否在過去12個月內(或登記人被要求提交此類文件的較短時間內)按照《S-t規則》第405條(本章第232.405條)提交了每個必須提交的交互式數據文件。☒     ☐ 否

 

勾選以下選框,指示申報人是大型加速評估提交人、加速評估提交人、非加速評估提交人、小型報告公司或新興成長型公司。關於「大型加速評估提交人」、「加速評估提交人」、「小型報告公司」和「新興成長型公司」的定義,請參見《交易所法規》第12億.2條。

 

大型加速報告人

加速報告人

非加速報告人

小型報告公司

 

 

新興成長公司

 

如果是新興成長型企業,請勾選此項,表示註冊者已選擇不使用根據《交易所法》第13(a)條提供的任何新的或修訂後的財務會計準則的延長過渡期進行遵守。

 

請勾選是否爲外殼公司(根據《交易所法》規定的定義在規則12b-2中) 是 ☒ 否

 

請指明截至最近可行日期,各發行人普通股類別的流通股份數量。

 

截至2024年12月19日,註冊人擁有 1,040,924 每股面值0.001美元的普通股,已發行。

 

 

 

 

目錄

 

第一部分 - 財務信息

 

 

 

 

 

 

 

 

項目1.

中期簡明合併基本報表

 

4

 

 

 

 

 

 

項目2.

管理層對控件和經營結果的討論與分析

 

29

 

 

 

 

 

 

項目3。

關於市場風險的定量和定性披露

 

31

 

 

 

 

 

 

項目4。

控制和程序

 

31

 

 

 

 

 

第二部分 - 其他信息

 

 

 

 

 

 

 

 

項目1.

法律訴訟

 

33

 

 

 

 

 

 

項目1A。

Risk Factors

 

33

 

 

 

 

 

 

項目2.

未註冊的股票證券銷售及收益使用

 

33

 

 

 

 

 

 

項目3。

高級證券的缺省

 

33

 

 

 

 

 

 

項目4。

礦業安全披露

 

33

 

 

 

 

 

 

第五項。

其他信息

 

33

 

 

 

 

 

 

第六項。

展覽品

 

34

 

 

 

 

 

 

簽名

 

35

 

 
2

目錄

 

前瞻性聲明

 

本季報包含前瞻性陳述。這些陳述與未來事件或我們未來的財務表現相關。在某些情況下,您可以通過諸如「可能」、「應該」、「期望」、「計劃」、「預期」、「相信」、「估計」、「預測」、「潛在」或「繼續」這些術語或它們的否定形式或其他可比術語來識別前瞻性陳述。這些陳述僅僅是預測,涉及已知和未知的風險、不確定性和其他因素,這些因素可能導致我們或我們行業的實際結果、活動水平、表現或成就與任何未來結果、活動水平、表現或成就在實質上有顯著不同。儘管我們相信前瞻性陳述所反映的期望是合理的,但我們無法保證未來的結果、活動水平、表現或成就。

 

我們的未經審計的簡明合併基本報表是根據美國公認會計原則編制的。以下討論應與我們在本季度報告中出現的未經審計的簡明合併基本報表及相關附註一同閱讀。以下討論包含反映我們計劃、估算和信念的前瞻性聲明。我們的實際結果可能與前瞻性聲明中討論的結果有重大差異。可能導致或促成這種差異的因素包括但不限於以下討論的內容以及本季度報告中的其他內容。

 

這些以及其他可能影響我們業務的風險和不確定性的描述出現在我們2024年12月16日提交給證券交易委員會(「SEC」)的10-K表格的「風險因素」部分。 "風險因素"下描述的風險和不確定性並不窮盡。

 

在本季度報告中,除非另有說明,所有金額均以美元表示,所有對「普通股」的引用均指我們普通股的股份。

 

在本季度報告中,術語「我們」、「我們公司」、「我們的」和「我們的公司」指的是Upexi, Inc.,除非另有說明。

 

 
3

目錄

 

第一部分 - 財務信息

 

項目1. 財務報表

 

UPEXI公司

 

未經審計的臨時簡明合併基本報表

截至2024年和2023年9月30日的三個月期間

 

 

 

 

 

 

 

 

截至2024年9月30日(未經審計)的合併資產負債表和2024年6月30日

 

5

 

 

 

 

 

截至2024年和2023年9月30日的三個月合併經營報表(未經審計)

 

6

 

 

 

 

 

截至2024年和2023年9月30日的三個月合併股東權益報表(未經審計)

 

7

 

 

 

 

截至2024年和2023年9月30日的三個月合併現金流量表(未經審計)

 

8

 

 

 

 

 

未經審計的簡明合併財務報表附註。

 

9

 

 
4

目錄

 

UPEXI公司

凝縮的合併資產負債表

 

 

 

9月30日,

 

 

6月30日

 

 

 

 

2024

 

 

2024

 

 

 

 

(未經審計) 

 

 

 

 

資產

 

 

 

 

 

 

 

流動資產

 

 

 

 

 

 

 

現金

 

$1,790,391

 

 

$661,415

 

應收賬款,淨額

 

 

801,442

 

 

 

606,885

 

存貨淨額

 

 

1,636,419

 

 

 

1,431,556

 

來自VitaMedica的過渡款項

 

 

171,218

 

 

 

212,358

 

預付費用和其他應收款

 

 

390,810

 

 

 

502,188

 

待售資產 - 建築

 

 

-

 

 

 

4,005,516

 

應收購價 - VitaMedica

 

 

2,000,000

 

 

 

2,000,000

 

應收購價 - E-core

 

 

-

 

 

 

2,000,000

 

總流動資產

 

 

6,790,280

 

 

 

11,419,918

 

 

 

 

 

 

 

 

 

 

物業及設備(淨額)

 

 

2,338,199

 

 

 

2,356,556

 

無形資產,淨值

 

 

220,681

 

 

 

239,871

 

商譽

 

 

848,854

 

 

 

848,854

 

遞延所得稅資產

 

 

5,948,858

 

 

 

5,948,858

 

其他資產

 

 

206,360

 

 

 

278,435

 

使用權資產,淨額

 

 

2,249,796

 

 

 

2,418,596

 

其他資產總計

 

 

11,812,748

 

 

 

12,091,170

 

 

 

 

 

 

 

 

 

 

總資產

 

$18,603,028

 

 

$23,511,088

 

 

 

 

 

 

 

 

 

 

負債及股東權益

 

 

 

 

 

 

 

 

流動負債

 

 

 

 

 

 

 

 

應付賬款

 

$575,238

 

 

$481,647

 

應計補償

 

 

952,601

 

 

 

1,098,856

 

遞延收入

 

 

178,016

 

 

 

235,255

 

應計負債

 

 

317,239

 

 

 

736,407

 

應計利息

 

 

453,280

 

 

 

476,018

 

收購應付款

 

 

413,152

 

 

 

413,152

 

關聯方預付款,淨額

 

 

-

 

 

 

100,000

 

流動部分應付票據

 

 

140,000

 

 

 

-

 

流動部分可轉換票據應付

 

 

387,500

 

 

 

-

 

當前應付相關方票據的部分

 

 

125,000

 

 

 

-

 

當前應付Cygnet子公司的票據部分

 

 

5,447,565

 

 

 

5,447,565

 

待售建築物的應付票據

 

 

-

 

 

 

2,634,538

 

當前應付的運營租賃負債部分

 

 

781,810

 

 

 

1,031,714

 

 

 

 

 

 

 

 

 

 

總流動負債

 

 

9,771,401

 

 

 

12,655,152

 

 

 

 

 

 

 

 

 

 

經營租賃應付賬款,扣除當前部分

 

 

1,842,505

 

 

 

1,732,606

 

相關方應付票據

 

 

375,000

 

 

 

500,000

 

應付票據

 

 

420,000

 

 

 

557,429

 

可轉換票據應付

 

 

1,162,500

 

 

 

1,550,000

 

 

 

 

 

 

 

 

 

 

長期負債總額

 

 

3,800,005

 

 

 

4,340,035

 

 

 

 

 

 

 

 

 

 

承諾與或有事項

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

股東權益

 

 

 

 

 

 

 

 

優先股,$0.001 面值, 100,000,000 授權股份,和 25,00025,000 發行的股份和流通的股份,分別爲

 

 

25

 

 

 

25

 

普通股,$0.001 面值, 100,000,000 授權股份,和 1,045,4291,045,429 發行的股份和流通的股份,分別爲

 

 

1,045

 

 

 

1,045

 

額外實收資本

 

 

53,515,742

 

 

 

53,374,444

 

累計虧損

 

 

(48,485,190 )

 

 

(46,859,613 )

股東權益總額

 

 

5,031,622

 

 

 

6,515,901

 

 

 

 

 

 

 

 

 

 

總負債和股東權益

 

$18,603,028

 

 

$23,511,088

 

 

附帶的說明是這些未經審計的簡明合併基本報表的一個不可或缺的部分。

 

 
5

目錄

 

UPEXI公司

壓縮合並運營報表(未經審計)

 

 

截止三個月

九月三十日

 

 

 

2024

 

 

2023

 

 

 

 

 

 

 

 

營業收入

 

 

 

 

 

 

營業收入

 

$4,356,515

 

 

$8,274,690

 

 

 

 

 

 

 

 

 

 

營業收入成本

 

 

1,426,447

 

 

 

2,845,201

 

 

 

 

 

 

 

 

 

 

毛利潤

 

 

2,930,068

 

 

 

5,429,489

 

 

 

 

 

 

 

 

 

 

營業費用

 

 

 

 

 

 

 

 

銷售和市場營銷

 

 

1,041,425

 

 

 

1,816,702

 

分銷成本

 

 

1,455,725

 

 

 

2,131,892

 

一般及行政費用

 

 

1,367,690

 

 

 

1,578,350

 

基於股份的薪酬

 

 

141,298

 

 

 

421,887

 

商譽無形資產攤銷

 

 

19,190

 

 

 

658,858

 

折舊

 

 

239,905

 

 

 

277,613

 

 

 

 

4,265,233

 

 

 

6,885,302

 

 

 

 

 

 

 

 

 

 

運營損失

 

 

(1,335,165 )

 

 

(1,455,813 )

 

 

 

 

 

 

 

 

 

其他費用,淨額

 

 

 

 

 

 

 

 

其他

 

 

-

 

 

 

(9,808 )

利息費用,淨額

 

 

(290,412 )

 

 

(843,475 )

 

 

 

 

 

 

 

 

 

其他費用,淨額

 

 

(290,412 )

 

 

(853,283 )

 

 

 

 

 

 

 

 

 

營業收入稅前的損失

 

 

(1,625,577 )

 

 

(2,309,096 )

 

 

 

 

 

 

 

 

 

所得稅收益

 

 

-

 

 

 

472,367

 

 

 

 

-

 

 

 

472,367

 

 

 

 

 

 

 

 

 

 

持續經營的淨虧損

 

 

(1,625,577 )

 

 

(1,836,729 )

 

 

 

 

 

 

 

 

 

出售收益來自於:

 

 

 

 

 

 

 

 

互動優惠

 

 

-

 

 

 

380,624

 

 

 

 

-

 

 

 

380,624

 

 

 

 

 

 

 

 

 

 

停止運營的收入(損失)

 

 

 

 

 

 

 

 

互動優惠

 

 

-

 

 

 

(193,040 )

維塔醫學

 

 

-

 

 

 

69,406

 

E-core

 

 

-

 

 

 

224,351

 

收入已中止的業務

 

 

-

 

 

 

100,717

 

 

 

 

 

 

 

 

 

 

歸屬於Upexi,Inc.的淨損失

 

$(1,625,577 )

 

$(1,355,388 )

 

 

 

 

 

 

 

 

 

每股基本收入(虧損):

 

 

 

 

 

 

 

 

持續經營的每股虧損

 

$(1.55 )

 

$(1.81 )

終止經營的每股收入

 

$-

 

 

$0.10

 

歸屬於Upexi股東的每股總收入(損失)

 

$(1.55 )

 

$(1.34 )

 

 

 

 

 

 

 

 

 

攤薄後的每股收入(損失):

 

 

 

 

 

 

 

 

持續經營的每股虧損

 

$(1.55 )

 

$(1.81 )

終止經營的每股收入

 

$-

 

 

$0.10

 

歸屬於Upexi股東的每股總損失

 

$(1.55 )

 

$(1.34 )

 

 

 

 

 

 

 

 

 

基本加權平均流通股數

 

 

1,045,429

 

 

 

1,012,231

 

完全攤薄加權平均流通股數

 

 

1,045,429

 

 

 

1,012,231

 

 

附帶的說明是這些未經審計的簡明合併基本報表的一個組成部分。

 

 
6

目錄

 

UPEXI公司

濃縮合並股東權益報表(未經審計)

 

 

優先股

 

 

優先股

 

 

普通股

 

 

普通股

 

 

額外支付

 

 

累積

 

 

非控制性

 

 

總股東的

 

 

 

股票

 

 

平局

 

 

股票

 

 

平局

 

 

在資本中

 

 

赤字

 

 

利息

 

 

股權

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2023

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

截至2023年6月30日的餘額

 

 

25,000

 

 

$25

 

 

 

1,010,843

 

 

$1,011

 

 

$51,541,909

 

 

$(23,201,175)

 

$(505,147 )

 

$27,836,623

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

發行股票和股權以購買Cygnet

 

 

 

 

 

 

 

 

 

 

4,505

 

 

 

5

 

 

 

162,722

 

 

 

 

 

 

 

505,147

 

 

 

667,874

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

基於股票的補償

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

421,887

 

 

 

-

 

 

 

-

 

 

 

421,887

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

截至2023年9月30日的三個月淨虧損

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(1,355,388 )

 

 

-

 

 

 

(1,355,388 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

截至2023年9月30日的餘額

 

 

25,000

 

 

$25

 

 

 

1,015,348

 

 

$1,016

 

 

$52,126,518

 

 

$(24,556,563 )

 

$-

 

 

$27,570,996

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2024

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

餘額,2024年6月30日

 

 

25,000

 

 

$25

 

 

 

1,045,429

 

 

$1,045

 

 

$53,374,444

 

 

$(46,859,613 )

 

$-

 

 

$6,515,901

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

基於股票的補償

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

141,298

 

 

 

-

 

 

 

-

 

 

 

141,298

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

截至2024年9月30日的三個月淨虧損

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(1,625,577 )

 

 

-

 

 

 

(1,625,577 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

餘額,2024年9月30日

 

 

25,000

 

 

$25

 

 

 

1,045,429

 

 

$1,045

 

 

$53,515,742

 

 

$(48,485,190 )

 

$-

 

 

$5,031,622

 

 

附帶的說明是這些未經審計的簡明合併基本報表的一個不可或缺的部分。

 

 
7

目錄

 

UPEXI公司

壓縮合並現金流量表(未經審計)

 

 

 

三個月結束

九月三十日

 

 

 

2024

 

 

2023

 

經營活動產生的現金流

 

 

 

 

 

 

經營活動淨虧損

 

$(1,625,577 )

 

$(1,355,388 )

 

 

 

 

 

 

 

 

 

調整經營活動淨虧損與用於經營活動的淨現金的對賬:

 

 

 

 

 

 

 

 

折舊和攤銷

 

 

259,095

 

 

 

936,471

 

貸款成本攤銷

 

 

2,571

 

 

 

23,708

 

考慮折扣攤銷

 

 

-

 

 

 

363,412

 

遞延稅資產變動

 

 

-

 

 

 

(472,367 )

基於股票的補償

 

 

141,298

 

 

 

421,887

 

資產和負債變動,扣除獲得金額

 

 

 

 

 

 

 

 

應收賬款

 

 

(194,557 )

 

 

(1,323,364 )

庫存

 

 

(204,863 )

 

 

(1,856,684 )

預付費用和其他資產

 

 

170,455

 

 

 

306,369

 

經營租賃資產和負債淨額

 

 

28,795

 

 

 

(63,022 )

應付賬款和應計負債

 

 

(494,570 )

 

 

925,927

 

遞延收入

 

 

(57,239 )

 

 

19,819

 

經營活動產生的淨現金使用 - 持續經營

 

 

(1,974,592 )

 

 

(2,073,232 )

經營活動產生的淨現金使用 - 停業經營

 

 

-

 

 

 

(1,718,972 )

淨現金流出活動

 

 

(1,974,592 )

 

 

(3,792,204 )

 

 

 

 

 

 

 

 

 

投資活動產生的現金流量

 

 

 

 

 

 

 

 

出售建築物的收益,淨額

 

 

4,005,516

 

 

 

-

 

出售E-core的收益

 

 

2,000,000

 

 

 

-

 

出售互動優惠的收益,扣除支付的負債

 

 

-

 

 

 

940,000

 

收購Cygnet Online LLC,淨額

 

 

-

 

 

 

(500,000 )

購置物業和設備

 

 

(167,410 )

 

 

(294,676 )

來自投資活動的淨現金 - 持續業務

 

 

5,838,106

 

 

 

145,324

 

投資活動提供的淨現金

 

 

5,838,106

 

 

 

145,324

 

 

 

 

 

 

 

 

 

 

融資活動產生的現金流

 

 

 

 

 

 

 

 

支付收購應付票據

 

 

-

 

 

 

(265,569 )

來自關聯方墊款的收入

 

 

(100,000 )

 

 

-

 

建築物應付票據的收入

 

 

(2,634,538

)

 

 

(60,373 )

用於融資活動的淨現金 - 持續業務

 

 

(2,734,538 )

 

 

(325,942 )

 

 

 

 

 

 

 

 

 

融資活動所使用的淨現金

 

 

(2,734,538 )

 

 

(325,942 )

 

 

 

 

 

 

 

 

 

現金淨增加(減少) - 持續業務

 

 

1,128,976

 

 

 

(2,253,850 )

現金淨減少 - 已終止業務

 

 

-

 

 

 

(1,718,972 )

 

 

 

 

 

 

 

 

 

現金,期初餘額

 

 

661,415

 

 

 

4,492,291

 

現金,期末餘額

 

$1,790,391

 

 

$519,469

 

 

 

 

 

 

 

 

 

 

現金流量補充披露

 

 

 

 

 

 

 

 

支付的利息

 

$84,362

 

 

$94,860

 

已支付的所得稅

 

$-

 

 

$-

 

非現金投資和融資活動

 

 

 

 

 

 

 

 

發行普通股以收購Cygnet

 

$-

 

 

$162,727

 

發行債務以收購Cygnet

 

$-

 

 

$300,000

 

Bloomios以非現金方式支付應收賬款,淨額

 

$-

 

 

$845,443

 

 

附帶的說明是這些未經審計的簡明合併基本報表的一個不可或缺的部分。

 

 
8

目錄

 

UPEXI公司

簡明聯合財務報表附註(未經審計)

 

註釋 1. 背景信息

 

在本季度報告中,除非另有說明,術語"我們"、"我們"、"我們的"、"Upexi"和"公司"指的是Upexi, Inc.,一家成立於2018年的內華達州公司。公司擁有十一家活躍的子公司,包括:

 

 

HAVZ, LLC,商業名稱爲Steam Wholesale,位於加利福尼亞的有限責任公司

 

☐ 

Gummy Labs, LLC,位於德拉瓦的有限責任公司

 

MW Products, Inc.,位於內華達的公司

 

Upexi Holding, LLC,位於德拉瓦的有限責任公司

 

 

o

Upexi寵物產品公司,有限責任公司,特拉華州

 

Upexi企業公司,有限責任公司,特拉華州

 

 

o

Upexi分銷公司,有限責任公司,特拉華州

 

 

o

Upexi分銷管理公司,有限責任公司,特拉華州

 

 

o

Upexi物業與資產公司,有限責任公司,特拉華州

 

 

 

Upexi 17129佛羅里達州公司,有限責任公司,特拉華州

 

Cygnet Online, LLC(「Cygnet」),一家特拉華州有限責任公司(截至2023年9月1日100%擁有)

 

以下子公司在截至2024年9月30日和2023年9月30日的三個月內沒有任何活動:

 

 

Upexi CP, LLC,一家特拉華州有限責任公司

 

☐ 

Upexi CP / Canada Inc.,一家加拿大公司

 

Prax Products, LLC,一家佛羅里達州有限責任公司

 

Upexi Development and Marketing, LLC,一家特拉華州有限責任公司

 

Trunano Labs, Inc.是一家內華達州公司

 

截至2024年6月30日的財年中,以下子公司已被剝離,截止2023年9月30日的三個月內的所有業務均被歸類爲停業業務:

 

 

VitaMedica公司,內華達州公司

 

☐ 

E-Core科技公司,佛羅里達州公司

 

Interactive Offers有限責任公司,特拉華州有限責任公司

 

此外,公司擁有六家全資子公司,在截至2023年9月30日的三個月內沒有任何活動。所有實體均已於2024年6月30日被解散或註銷。

 

 

·

Steam Distribution, LLC,是一家位於加利福尼亞的有限責任公司

 

·

One Hit Wonder, Inc.,是一家加利福尼亞州的公司

 

·

One Hit Wonder Holdings, LLC,是一家位於加利福尼亞的有限責任公司

 

·

Vape Estate, Inc.,是一家內華達州的公司

 

·

SWCH, LLC,是一家位於特拉華州的有限責任公司

 

·

Cresco Management, LLC,是一家位於加利福尼亞的有限責任公司

 

 
9

目錄

我們的產品通過多個機構在美國和國際上分銷,並通過我們在佛羅里達的地點進行管理。

 

Upexi 總部位於佛羅里達州坦帕,我們的現場和遠程團隊爲所有品牌推動直銷、批發和亞馬遜銷售。坦帕地點還爲所有其他地點提供會計、企業監督、日常財務、業務發展和運營管理支持。

 

MW產品 我們的公司總部以及佛羅里達州坦帕的倉庫運營,管理直接面向消費的銷售、批發和亞馬遜銷售,爲多個品牌開發新產品,同時我們的研發團隊位於內華達州亨德森和佛羅里達州奧德薩。

 

幸運的尾巴 從我們在佛羅里達州坦帕的倉庫運營,銷售和市場由現場和遠程團隊驅動,這些團隊負責亞馬遜的銷售策略和日常業務運營。

 

HAVZ, LLC,以Steam爲名運營 批發 在佛羅里達州奧德薩經營製造業-半導體和/或分銷中心,支持我們的健康和保健產品,包括那些由大麻成分製造的產品以及我們的整體分銷業務。我們繼續以企業爲中心管理這些業務,專注於更大的機會,這些機會爲未來的大部分企業關注和投資提供了依據。

 

Upexi 分銷 從我們位於佛羅里達州坦帕的倉庫運營,提供倉儲、分銷及其他對我們產品銷售的支持服務。

 

註釋 2. 重要會計政策

 

遵循的重大會計政策包括:

 

估計的使用 -編制符合美國通用會計原則的合併基本報表要求管理層對資產和負債的報告金額以及合併基本報表日期的或有資產和負債的披露進行估算和假設,並影響報告期間的收入和費用的報告金額。實際結果可能與這些估算有所不同。

 

公司報告的財務狀況和經營結果所依據的重要估計包括壞賬準備、物業和設備的使用年限、長期資產的減值、存貨估值、股票期權補償的公允價值以及遞延所得稅資產的估值準備。

 

現金-公司將所有到期在三個月或更短的高度流動投資工具視爲現金等價物。現金保存在金融機構,有時餘額可能超過聯邦保險限額。公司從未經歷過與這些餘額相關的損失。

 

應收賬款 -應收款項是無擔保的客戶義務,按正常的交易條款在發票日期後的指定時間內要求支付。交易條款根據客戶的不同而有所變化,通常區間從預付到發票日期後的45天。公司不對逾期賬款收取利息。應收款項的賬面金額會根據管理層對預期信用損失的最佳估計,按需減少估值備抵。此估算考慮了歷史經驗、當前情況和適用的合理可支持的預測。實際結果可能與估計有所不同。當管理層認爲賬款無法收回時,會從備抵中扣除。2024年9月30日、2024年6月30日、2023年9月30日和2023年6月30日的淨應收賬款餘額爲$801,452, $606,885, $2,605,958 和 $1,125,394,分別爲。根據管理層對應收賬款的審查,估值備抵在2024年9月30日和2024年6月30日約爲$61,750 。公司在截止2024年9月30日的三個月和截止2023年9月30日的三個月內沒有壞賬費用。

 

 
10

目錄

 

庫存 - 公司每季度審查所有產品和原材料的庫存水平。對於大多數已在市場上銷售一年或更長時間的產品,我們認爲超過一年銷售量的庫存爲過剩庫存,或者顯示銷售速度低於預期的其他項目。由於我們的產品市場滲透有限,我們決定對某些原材料和成品的成本減記50%。不再作爲當前產品提供的產品被視爲過時。滯銷和過時庫存的潛在轉售價值取決於我們對未來需求和市場條件的假設。過時庫存的記錄成本隨後減少至零。滯銷和過時庫存被覈銷,並作爲營業成本的費用記錄。所有過時庫存的調整都爲該庫存建立了新的成本基礎,因爲我們認爲這種減少是產品市場價格的永久性下降。通常,過時庫存出售給專門從事清算的公司,而我們則繼續銷售滯銷庫存,直到它們被售出或變得過時。

 

庫存由原材料和成品組成,並按成本或淨可變現價值中的低者計量,成本是通過加權平均移動成本法確定的。淨可變現價值的確定適當考慮了過時、過剩、惡化和其他因素。 在2024年9月30日,公司有$497,160 的原材料和$1,139,259 的成品庫存。 在2024年6月30日,公司有$465,535 的原材料和$966,021 的成品庫存。 截至2024年6月30日,公司有$605,994 ,截至2024年9月30日和2023年的庫存準備爲$605,470 和 $65,994 分別。

 

物業及設備 -物業和設備以成本記錄。折舊採用直線法計算,按資產的預估使用壽命進行,壽命範圍爲 320 年。租賃改善按其預估使用壽命的較短期限進行攤銷,期限爲 5 年或相關租賃期限。處置時的收益和損失在處置期間反映在經營報告中。維護和修理支出按發生時計入費用。

 

商業組合 - 公司對其業務組合採用收購會計法進行覈算。收購成本以收購日期資產轉移的公允價值和公司承擔的負債的總和加上賣方現金對價和發行的股權工具進行衡量。直接與收購相關的交易成本在發生時作爲費用處理。收購總成本(i)的超過被收購方可識別淨資產公允價值(ii)的部分記錄爲可識別的無形資產和商譽。

 

商譽 - 公司定期評估其商譽是否可能減值,簡化商譽減值測試,至少每年進行一次,並在一個或多個觸發事件或情況表明商譽可能減值時進行。根據本指引,每年或每期進行商譽減值測試,通過比較報告單位的估計公允價值與其賬面價值進行。對於賬面價值超過報告單位公允價值的部分,將確認減值損失,但不得超過商譽的賬面價值。

公司分別於2024年6月30日和2023年進行年度測試。

 

管理層確定,到2024年6月30日,與Cygnet相關的商譽已完全減值,這是基於退出再採購業務的戰略決策。3,594,745 在2024年6月30日錄得商譽減值金額爲$,消除了所有與Cygnet相關的商譽。

 

管理層決定到2023年6月30日,因2023年9月1日業務的出售,Interactive Offers相關的商譽完全減值。2,889,158 在2023年6月30日記錄了金額爲$的商譽減值,消除了所有與Interactive Offers相關的商譽。

 

收入確認 -根據ASC第606號《客戶合同收入》,公司在滿足履行義務並將我們的產品或服務的控制權轉移給客戶時確認營業收入。一般來說,公司從產品銷售中產生營業收入,銷售對象可以是直接面向客戶或分銷商。在確定合同是否存在時,我們會評估協議的條款、與客戶或分銷商的關係以及他們的支付能力。

 

公司在銷售我們的產品時確認營業收入,包括對分銷商的銷售,通常在發貨或交付給客戶或分銷商時確認,具體取決於銷售訂單的條款。當所有權和風險轉移、客戶有支付義務時,以及在適用的情況下,當客戶接受產品或接受期滿時,控制權被視爲轉移。對於對分銷商的銷售,付款根據我們的標準商業條款到期,與分銷商的產品轉售無關。

 

 
11

目錄

 

客戶支付的運費和手續費包含在營業收入中。與入境貨物相關的運費和手續費一般包含在營業收入成本中。

 

我們的業務受客戶訂單相關的不確定性影響,包括:

 

回歸權利:

 

我們的大部分營業收入來自可消費產品的銷售,這些產品的成交量大但數量少,通常在我們設施中的庫存水平保持在九十天以內。客戶退貨在歷史上每年僅佔銷售的一個很小比例。其他產品的銷售與一些寵物產品有關,包括小型機械設備。

 

保修:

 

公司不接受批發客戶的銷售退貨,因爲產品在生產和發貨前已獲得批准。電子商務產品的退貨必須在購買日期後的45天內完成。公司根據歷史經驗和管理層對未來費用的估計,計提客戶服務在產品發貨後的退款、退還按金和折扣的準備金,包括更換、運費和其他履行費用。

 

接受條件:

 

我們的消費品和寵物產品的銷售通常沒有客戶驗收條款。

 

合同資產

 

合同資產是公司在向客戶轉移貨物或服務後,獲得的對價權利。ASC 606《客戶合同的收入》根據對價的收取是否依賴於時間以外的其他條件,區分合同資產和應收款項。當公司在客戶支付對價之前將控制權轉移給客戶時,公司會根據其對價權利的性質記錄合同資產或應收款項。合同資產轉變爲應收賬款的時點可能早於發票開具的時點。公司根據ASC 310《應收款項》對合同資產進行減值評估。

 

下表披露了分項營業收入:

 

 

 

9月30日,

2024

 

 

2023年9月30日,

2023

 

主要地理市場

 

 

 

 

 

 

 

 

 

 

 

 

 

美利堅合衆國

 

$4,280,593

 

 

$8,162,728

 

其他

 

 

75,922

 

 

 

111,962

 

 

 

$4,356,515

 

 

$8,274,690

 

總計

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

產品來源

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

內部生產

 

$2,166,341

 

 

$3,076,342

 

合同製造

 

 

578,316

 

 

 

802,503

 

作爲成品採購

 

 

1,611,858

 

 

 

4,395,845

 

 

 

 

 

 

 

 

 

 

總計

 

$4,356,515

 

 

$8,274,690

 

 

以下表格顯示了遞延營業收入:

 

 

 

9月30日,

2024

 

 

6月30日

2024

 

遞延收入

 

$178,016

 

 

$235,255

 

 

遞延營業收入或稱爲資金積壓爲$178,016 和 $235,255截至2024年9月30日和2024年6月30日,分別爲。我們確認了大約$210,000 在截至2024年9月30日的三個月內,預計將在截至2025年6月30日的年度內確認大約100%的遞延營業收入作爲營業收入。在截至2023年9月30日的三個月內,2023年6月30日沒有開盤負債餘額需要確認。

 

長期資產減值 -開多資產在事件或環境變化表明資產的賬面價值可能無法收回時會進行減值審查。公司定期評估是否發生了表明可能減值的事件和環境。當存在減值因數時,公司通過測量相關資產或資產組在剩餘使用壽命內的未來未折現淨現金流來估計資產價值是否可收回。

 

 
12

目錄

 

 

廣告 - 公司通過廣告支持其產品,以提高公司各類產品的品牌知名度,此外還有公司市場營銷團隊執行的其他營銷項目。公司認爲持續投資於廣告對其品牌產品的開發和銷售至關重要。廣告費用爲$194,774 和 $287,146 在截至2024年9月30日和2023年9月30日的三個月期間,費用已計入當期損益。

 

基於股票的補償 - 公司在合併基本報表中確認對員工的所有基於股份的支付,包括員工期權的授予和限制性股票的授予,作爲補償費用,基於其公允價值進行確認。這筆費用將在員工需要提供服務以換取獎勵的期間內確認,該期間稱爲必需服務期(通常是歸屬期),如果基於股份的支付立即歸屬,則立即確認。

 

非員工以股票爲基礎的付款 -公司爲換取商品和服務而向顧問和供應商發行的權益工具的會計政策遵循了會計準則編纂(ASC)2018-07的規定,該法簡化了基於非員工股份的支付交易的會計。修正案規定,主題718適用於所有基於股份的支付交易,在這些交易中,設保人通過發放基於股份的支付獎勵獲得供設保人自己的業務使用或消費的商品或服務。與非僱員相關的股票付款是根據相關股票或期權的公允價值或服務的公允價值計算的,以更容易確定的爲準。已發行股票工具公允價值的計量日期在 (i) 顧問或供應商達成履約承諾之日或 (ii) 顧問或供應商業績完成之日中以較早者爲準。對於向顧問發行的股票工具,股票工具的公允價值在諮詢協議的期限內予以確認。

 

公允價值計量 - 公司依據FASB ASC 820 "公允價值計量和披露" (ASC 820) 進行金融工具的會計處理。ASC 820定義了公允價值,建立了公允價值計量的框架,並擴展了關於公允價值計量的披露。ASC 820將公允價值定義爲在主要市場或對資產或負債的最有利市場中,市場參與者在計量日進行有序交易時,資產的交換價格或轉移負債的支付價格(退出價格)。ASC 820還建立了公允價值等級結構,區分 (1) 基於從獨立來源獲得的市場數據(可觀察輸入)所開發的市場參與者假設,以及 (2) 實體自身關於市場參與者假設的假設,這些假設是基於特定情況下最優可用信息而開發的(不可觀察輸入)。

 

公允價值層級由三個大層級組成,最高優先級給予在活躍市場中相同資產或負債的未調整報價(一級),最低優先級則給予不可觀察的輸入(二級)。公允價值層級的三個層級描述如下:

 

 

·

第一級 - 在測量日期可用於相同、無條件資產或負債的活躍市場中的未調整報價價格。

 

 

 

 

·

第二級 - 第一級中包含的、其他可觀察的資產或負債的輸入,直接或間接可觀察,包括活躍市場中類似資產或負債的報價價格;在不活躍的市場中相同或相似資產或負債的報價價格;其他可觀察的資產或負債的輸入(例如,利率期貨);以及主要由可觀察市場數據通過關聯或其他方式得出的輸入。

 

 

 

 

·

第三級 - 對公允價值測量既重要又不可觀察的輸入。

 

 
13

目錄

 

某些金融工具的估計公允價值,包括現金、應收賬款、應付賬款、應計費用、遞延營業收入和債務,按照歷史成本計量,由於這些工具的短期性質,其公允價值與歷史成本相近。

 

租賃 - 公司在合同生效時確定合同是否包含租賃。如果合同傳達了在一段時間內控制特定資產使用權的權利以換取報酬,則該合同包含租賃。控制被定義爲擁有從資產使用中獲得實質上所有經濟利益的權利和指導資產使用的權利。管理層僅在合同條款和條件發生變更時重新評估其判斷。初始期限爲12個月或更短的租賃不會記錄在隨附的合併資產負債表中。公認會計原則要求公司在財務報告中對租賃進行評估,並將其分類爲經營租賃或融資租賃。分類評估從開始日期開始,評估中使用的租賃期限包括公司有權使用相關資產的不可取消期,以及在行使續租選項時合理確定的續租選項期,未行使該選項將導致經濟處罰。公司的所有房地產業租賃均被分類爲經營租賃。

 

大多數房地產業租賃合同包括一個或多個續租的期權,續租條款通常可以將租期延長兩年。行使續租期權由公司自行決定。公司在租賃開始時及持續過程中評估續租期權,並在分類租賃和衡量租賃負債時,將其合理確定會行使的續租期權納入預期租期。租賃協議通常不要求實質性的變量租賃支付、殘值擔保或限制性契約。

 

公司的租賃通常不提供隱含利率,因此在衡量經營租賃負債時,公司使用其增量借款利率作爲折現率。增量借款利率代表公司在租賃開始時,爲了在特定貨幣環境下以抵押方式借入與租賃付款相等的金額而需承擔的利率估算。

 

所得稅 -所得稅是針對合併基本報表中報告的交易的稅務影響提供的,包括當前到期的稅款和由於暫時性差異而產生的遞延稅款。這些暫時性差異源於資產和負債在稅務和財務報告目的上的賬面價值差異。遞延稅資產和負債代表這些差異的未來稅務後果,當資產和負債被回收或結算時,它們將成爲應納稅款或可扣除款項。如果根據可用的正面和負面證據的權重,遞延稅資產的一部分或全部不太可能被實現,則提供評估備抵以減少報告的遞延稅資產。  一個 $6,535,000 和一個 $6,100,000 評估備抵於2024年9月30日和2024年6月30日記錄。 

 

公司識別和評估不確定的稅務立場(如有),並確認在相關稅務機關審查時,該立場被支持的可能性低於大概率的影響。這些立場被視爲未確認的稅收利益,並在資產負債表上確立相應的負債。公司尚未爲不確定的稅務立場確認負債。如果存在未確認的稅收利益,公司將確認與未確認的稅收利益相關的利息費用在利息支出中以及罰款在營業費用中。

 

公司根據ASC 第740章「所得稅」採用資產和負債法進行所得稅會計。在該方法下,所得稅費用爲以下金額的確認:(i)當前年度應付或可退還的稅款和(ii)由於已經在實體的合併基本報表或納稅申報表中確認的事項產生的臨時差異的遞延稅務後果。遞延稅務資產和負債的計量使用預期適用於將在未來年度中恢復或結算的應納稅所得的已頒佈稅率。

 

 
14

目錄

稅率變動對遞延稅資產和負債的影響在包括法律生效日期的期間內被確認在經營結果中。

 

ASC主題740澄清了在企業合併基本報表中確認收入稅不確定性的會計處理,並規定了稅務申報中採取或預計採取的稅務位置的確認閾值和計量屬性。ASC主題740提供了關於去確認、分類、利息和罰款、季度期間的會計處理、披露和過渡的指導。在2024年9月30日或2024年6月30日沒有實質性的不確定稅務位置。

 

2017年12月22日,美國政府通過了稅法,該法案對1986年修訂的《國內稅收法典》進行了重大修改,包括但不限於降低美國公司法定稅率,以及2017年12月31日後產生的淨營業虧損可以無限期結轉,並且禁止將兩年的淨營業虧損進行回溯。

 

反向股票拆分

 

在2024年9月18日,我們向內華達州國務卿提交了變更證書,以按照1比20的比例實施普通股的反向股票拆分("反向股票拆分"),該拆分於2024年10月3日生效("生效日期")。反向股票拆分得到了董事會根據內華達州法律的批准。反向股票拆分對普通股的面值沒有影響。

 

在生效日期,每20股已發行和流通的普通股自動合併爲1股普通股,且每股面值沒有發生變化。由於每股面值沒有變化,我們在生效日期將$從普通股重新分類爲附加實收資本。19,860 未行使的股票期權、股權獎勵和Warrants的行使價格以及可以根據各自條款行使的股票數量,以及未來在股權激勵計劃下可發行的股票數量均已作出調整。反向股票拆分影響了所有股東,並未改變任何股東在我們普通股中的百分比權益。我們在反向股票拆分中並未發行任何碎股。相反,碎股最初被四捨五入到下一個最大整數,因此於2024年10月3日生效日期發行了8股,並於2024年10月8日增加發行了 38 普通股以便進行碎股的四捨五入。2024年10月10日,過戶代理收到了額外的請求,要求總共發行 202,183 普通股。這些股份於2024年10月23日發行,2024年10月30日我們被通知這些股被退還給公司的過戶代理。儘管公司在發行後確實收回了普通股,潛在的稀釋風險依然存在,並且這是公司在美國內華達州地區法院提起訴訟的主題,目的是消除任何這種風險。反向股票拆分並未修改普通股的相對權利或優先權。

 

除非另有說明,所有已發行的普通股和所有未流通的證券,其持有人有權購買我們普通股或獲得我們普通股,包括期權、限制性股票單位以及按每股數據、股價和行使價格的Warrants,依據這些證券的條款,均已追溯調整,以反映反向股票拆分。

 

在2024年10月17日,公司收到了納斯達克證券市場有限責任公司(「納斯達克」)的書面通知(「合規通知」),通知公司已重新符合納斯達克上市規則5550(a)(2)的要求,該規則要求在納斯達克證券市場上市的公司保持每股最低買盤價爲1.00美元。納斯達克在合規通知中告知公司,從2024年10月3日至2024年10月16日,公司普通股的收盤買盤價已達到每股1.00美元或更高,因此,公司已重新符合納斯達克上市規則5550(a)(2),該事項現已結案。

 

遞延收入 - 當客戶提前付款以購買產品時,公司的存入資金會被記錄爲遞延營業收入。產品發貨後,存入資金被記錄爲營業收入,相關佣金也會被支付。所有與遞延營業收入有關的產品均在一年以內發貨。

 

 
15

目錄

 

可轉換債務和證券 - 公司遵循ASC 470-20中關於有利轉化特徵的指引,這適用於可轉換股票以及可轉換債務。有利轉化特徵被定義爲在承諾日期內處於有利狀態的不可分離轉換特徵。有利轉化特徵的指引要求對轉換選項的有利部分,即選項的內在價值,在股本中確認,同時對該工具的賬面金額進行相應的減少。如果存在明確的到期日,則產生的折扣將在該工具的生命週期內按利息攤銷;如果沒有明確的到期日,則在最早的轉換日期攤銷。如果最早的轉換日期是在發行時立即進行,則必須在成立時確認費用。當基於未來事件對轉換比率進行後續變更時,新轉換價格可能會觸發在事件發生時確認額外的有利轉化特徵。

 

合併基本報表中的非控制性權益 - 2007年12月,FASB發佈了ASC 810-10-65,"合併基本報表中的非控制性權益"。該ASC澄清了對附屬公司的非控制性(少數)權益是對實體的所有權利益,應該在合併基本報表中報告爲股本。它還要求合併凈利潤包括歸屬於母公司和非控制性權益的金額,並在合併利潤表的表面披露歸屬於母公司和非控制性權益的金額。根據ASC 810-10-45-21,歸屬於母公司和附屬公司非控制性權益的損失可能超過其在子公司股本中的權益。即使這種歸屬導致非控制性權益餘額爲赤字,超出部分和任何歸屬於母公司和非控制性權益的進一步損失也應歸屬性於這些權益。

 

重新分類 - 截至2023年9月30日的合併基本報表進行了某些重分類,以符合截至2024年9月30日的展示。

 

編制基礎和合並原則 - 公司的簡明合併基本報表是根據美國普遍接受的會計原則("GAAP")編制的。簡明合併基本報表包括截至2024年9月30日和2024年6月30日公司持有控制性財務權益的所有子公司的賬戶。

 

管理層認爲,爲了公允呈現,所有必要的調整(包括正常的經常性調整)均已包含在內。截止2024年9月30日的三個月運營結果並不一定能反映2025年6月30日財年的預期結果。某些未經審核的臨時基本報表的附註將大幅重複2024財年經審計基本報表中的披露內容,因此被省略。該報告應與截止2024年6月30日的經審計基本報表及相關腳註共同閱讀,這些信息已作爲公司於2024年12月16日向證券交易委員會提交的10-K表單的一部分。

 

近期會計公告 – 不時會有新的會計公告由財務會計準則委員會("FASB")或其他標準制定機構發佈,並在指定的生效日期被我們採納。除非另有說明,否則最近發佈的不具備生效條件的標準對公司財務狀況或經營結果的採用不會產生重大影響。公司已考慮所有其他最近發佈的會計公告,包括與「當前預期信用損失」相關的ASC 326(「金融工具 - 信用損失」)的新規定。ASC 326已在2024財年採納,並對隨附的合併基本報表沒有產生重大影響。

 

注意 3. 庫存

 

庫存包括以下內容:

 

 

 

9月30日,

2024

 

 

6月30日

2024

 

原材料

 

$497,160

 

 

$465,535

 

成品

 

 

1,139,259

 

 

 

966,021

 

 

 

$1,636,419

 

 

$1,431,556

 

 

公司註銷被視爲過剩或過時的庫存價值。在截至2024年9月30日和2023年9月30日的三個月期間,公司註銷了價值爲$的庫存。42,370 和 $46,050截至2024年9月30日和2024年6月30日,公司擁有庫存儲備$。605,470 和 $605,470,分別爲。

 

 
16

目錄

 

注意 4. 不動產和設備

 

財產和設備包括以下內容:

 

 

 

9月30日,

2024

 

 

6月30日

2024

 

傢具和固定裝置

 

$127,029

 

 

$127,050

 

計算機設備

 

 

98,735

 

 

 

112,397

 

內部使用軟體

 

 

570,645

 

 

 

570,645

 

製造業設備

 

 

2,054,928

 

 

 

1,927,974

 

租賃改善

 

 

814,157

 

 

 

767,418

 

車輛

 

 

89,359

 

 

 

89,359

 

固定資產及設備,毛額

 

 

3,754,853

 

 

 

7,600,360

 

減少累計折舊

 

 

(1,416,654 )

 

 

(1,268,288 )

 

 

$2,338,199

 

 

$2,356,556

 

 

截至2024年和2023年9月30日的三個月折舊費用爲$239,905 和 $194,497,分別。

  

注5. 無形資產

 

截至2024年9月30日的無形資產:

 

 

 

預計

生命

 

成本

 

 

累計

攤銷

 

 

賬面價值

 

客戶關係

 

4

 

$1,834,692

 

 

$1,834,692

 

 

$-

 

交易名稱

 

5

 

 

383,792

 

 

 

163,111

 

 

 

220,681

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

在線銷售渠道

 

2

 

 

1,800,000

 

 

 

1,800,000

 

 

 

-

 

供應商關係

 

5

 

 

6,000,000

 

 

 

6,000,000

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$10,018,484

 

 

$9,797,803

 

 

$220,681

 

 

截至2024年和2023年9月30日的三個月內,公司的攤銷金額約爲$19,190 和 $1,186,800

 

截至2024年6月30日,無形資產:

 

 

 

預計

生命

 

成本

 

 

累計

攤銷

 

 

賬面價值

 

客戶關係

 

4

 

$1,834,692

 

 

$1,834,692

 

 

$-

 

交易名稱

 

5

 

 

383,792

 

 

 

143,921

 

 

 

239,871

 

在線銷售渠道

 

2

 

 

1,800,000

 

 

 

1,800,000

 

 

 

-

 

供應商關係

 

5

 

 

6,000,000

 

 

 

6,000,000

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$10,018,484

 

 

$9,778,613

 

 

$239,871

 

 

 
17

目錄

 

截至2024年9月30日,無形資產的未來攤銷如下:

 

2025年6月30日

 

$57,568

 

2026年6月30日

 

 

76,758

 

2027年6月30日

 

 

76,758

 

2028年6月30日

 

 

9,597

 

 

 

$220,681

 

 

註釋6. 預付費用及其他流動資產

 

預付賬款及其他應收款項包括以下內容:

 

 

 

9月30日,

2024

 

 

6月30日

2024

 

保險

 

$98,764

 

 

$116,074

 

預付款給供應商

 

 

208,869

 

 

 

203,556

 

服務的按金

 

 

21,512

 

 

 

25,550

 

預付的月租

 

 

38,452

 

 

 

60,041

 

在服務期間內攤銷的訂閱和服務

 

 

16,000

 

 

 

32,500

 

 

 

 

 

 

 

 

 

 

爲可轉換應付票據的預付利息而發行的股票

 

 

7,213

 

 

 

64,320

 

 

 

 

 

 

 

 

 

 

其他應收款

 

 

-

 

 

 

147

 

 

 

 

 

 

 

 

 

 

總計

 

$390,810

 

 

$502,188

 

 

所有板塊預付費用將在接下來的12個月內列支。

 

 
18

目錄

 

註釋 7. 經營租賃

 

我們已與多個不可撤銷的經營和融資租賃協議簽訂,涉及我們的一些辦公室、製造業以及設備。我們在安排開始時判斷該安排是否爲租賃或包含租賃,並在租賃開始時錄入我們的基本報表,該日期是出租方可供使用的基礎資產可用的日期。 我們的租賃條款可能包括一個或多個延長租賃期限的期權,期限從一年到20年不等。當我們有合理的確信將行使該期權時。截至2024年9月30日,未將任何延長租賃的期權確認爲使用權(「ROU」)資產和租賃負債。我們有租賃協議,包含租賃和非租賃元件,非租賃元件會單獨會計處理,並未包含在我們的ROU資產及相應負債中。我們選擇不在合併資產負債表上列示短期租賃,因爲這些租賃在租賃開始時的租期爲12個月或更短。

 

在2019年11月,公司簽訂了一份位於內華達的租賃合同,該合同於2019年11月13日生效,並記錄了一項使用權資產及相應的租賃負債。公司使用該租賃設施作爲辦公室、製造業和倉庫空間。根據某些運營租賃的條款,公司負責房地產稅、公共事業費和維修。在截至2024年6月30日的年度中,公司將該設施用於持續運營,並在截至2023年9月30日的三個月內確認了約$195,000 的費用。公司於2024年7月搬離該設施。

 

在2021年5月,公司簽訂了一項租賃合同,用於一個額外的內華達州設施,該合同於2021年5月1日開始生效,並記錄了使用權資產和相應的租賃負債。公司將這個租賃的設施用於額外的倉儲空間。最少租賃付款爲$0 和 $32,850 截至2024年和2023年9月30日的三個月,的租賃付款分別爲。公司在2024年4月租賃期結束時搬出了該設施。

 

在2018年11月期間,公司簽訂了一項設備租賃合同,該合同於2018年11月1日開始,並記錄了使用權資產和相應的租賃負債。租賃費用爲$1,910 和 $1,910 截至2024年和2023年9月30日的三個月的租賃費用分別爲。

 

2022年4月1日,公司收購了Cygnet,後者已於2021年10月8日開始租賃佛羅里達的設施,並記錄了使用權資產及相應的租賃負債。租賃到期日爲 2026年10月8日。公司將這一租賃設施用於倉庫和辦公室。根據某些經營租賃的條款,公司負責房地產業稅、公共事業費和維修,並將其作爲非租賃元件進行覈算,不包括在使用權內。租賃費用爲$0 和 $27,158 截至2024年和2023年9月30日的三個月分別爲$。公司於2023年10月放棄了該設施,並確認了$的租賃減值。289,969.

 

在2023年3月15日, 公司簽訂了一份租約,租賃位於佛羅里達州坦帕的約20,400平方英尺的倉庫和辦公空間,用作公司的配送中心。租約的初始期限爲三十八個月,在簽署租約時尚未完成。公司於2023年7月搬入該設施並開始運營。根據某些經營租約的條款,公司負責房地產業稅、公共事業費用和維修,這些費用被視爲元件,不包括在使用權資產(ROU)中。在截至2024年9月30日的三個月期間,公司確認了約$100,756 的費用,以及截至2023年9月30日的三個月期間的約$83,439 。   

 

2023年7月25日, 公司簽訂了一份租賃協議,租賃約5700平方英尺的辦公空間,位於佛羅里達州坦帕,作爲公司的企業總部。租賃的初始期限爲61個月。在截至2024年9月30日的三個月期間,公司確認了約$49,244 的費用,而截至2023年9月30日的年度未確認任何費用。

 

 
19

目錄

 

2024年4月1日, 公司與由我們的首席執行官阿倫·馬歇爾擁有的MFA 2510 Merchant LLC簽訂了一份租賃協議。租賃面積約爲10,000平方英尺的倉庫和辦公空間,位於佛羅里達州奧德薩,月租金爲20,060美元。租賃的初始期限爲五年。公司負責根據某些運營租賃的條款支付房地產業稅、公共事業費和維修費用,並會計處理爲非租賃元件,而不是ROU的一部分。公司花費了$611,768 用於對設施進行租賃改進,以準備產品製造,這將在五年的租賃期限內攤銷。產品製造在2024年8月1日已全面達到產能,並已完全從內華達州的設施轉移。截止2024年9月30日的三個月期間,公司確認了約$79,944 的費用。

 

經營租賃包含在經營使用權資產、流動和非流動經營租賃負債中,融資租賃則包含在物業、廠房和設備、應計費用和其他流動負債,以及合併資產負債表上的其他負債中。

 

下表將截止到2024年9月30日的不可撤銷的經營租賃(期限超過一年)下的未來最低租金(按年和合計顯示)與合併資產負債表中確認的總經營租賃負債進行對比。

 

2025

 

$853,420

 

2026

 

 

770,004

 

2027

 

 

507,343

 

2028

 

 

486,733

 

2029

 

 

221,715

 

未來最低租賃付款的總未折現金額

 

 

2,839,215

 

減:計入利息

 

 

(214,900 )

 

 

 

2,624,315

 

減去:當前部分

 

 

(781,810 )

經營租賃義務的現值

 

$1,842,505

 

 

Cygnet租賃的責任已包括在2025年的未折現未來最低租賃支付中。公司繼續與出租人合作,以解決爭議的租賃支付問題。

 

截至2024年9月30日,公司運營租賃的加權平均剩餘租期和加權平均折現率爲:

 

加權平均剩餘租賃期限

 

45 月份

 

加權平均增量借款利率

 

 

5.0%

 

截至2023年9月30日,公司的運營租賃加權平均剩餘租期和加權平均折現率爲:

 

加權平均剩餘租賃期限

 

44 月份

 

加權平均增量借款利率

 

 

5.0%

 

截至2024年和2023年9月30日的三個月,合併簡要財務報表中租賃費用的組成,包括一般和行政費用及利息費用,如下所示:

 

 

 

9月30日,

2024

 

 

9月30日

2023

 

融資租賃費用:

 

 

 

 

 

 

使用權資產的攤銷

 

$185,148

 

 

$170,970

 

利息支出

 

 

28,853

 

 

 

26,347

 

運營租賃成本

 

 

3,784

 

 

 

4,803

 

短期租賃費用

 

 

-

 

 

 

174,212

 

可變租賃費用

 

 

51,835

 

 

 

29,084

 

總租賃成本

 

$269,621

 

 

$405,416

 

 

 
20

目錄

 

註釋 8. 應計負債

 

應計負債包括以下內容:

 

             

 

9月30日,

2024

 

 

6月30日

2024

 

累計專業費用

 

 

169,222

 

 

 

312,500

 

應計銷售稅

 

 

25,394

 

 

 

28,539

 

其他應計負債

 

 

111,483

 

 

 

395,368

 

 

 

$306,099

 

 

$736,407

 

 

Acquisition Payable consists of the following:

 

               

 

September 30,

2024

 

 

June 30,

2024

 

Payments related to the acquisition of Cygnet

 

$-

 

 

$413,152

 

 

 

$-

 

 

$413,152

 

 

 
21

Table of Contents

 

Note 9. Convertible Promissory Notes and Notes Payable

 

Convertible promissory notes and notes payable outstanding as of September 30, 2024 and June 30, 2024 are summarized below:

 

 

 

Maturity

 

September 30,

 

 

June 30,

 

 

 

Date

 

2024

 

 

2024

 

Convertible Notes:

 

 

 

 

 

 

 

 

Promissory Note, 21- month term, as amended, 18.11% interest payable with common stock and subordinate to the Convertible Notes. This note was amended as of November 15, 2023, extending the note to June 1, 2026 and adjusted the interest rate to 12%, paid in cash monthly. 

 

June 1, 2026

 

$1,550,000

 

 

$1,550,000

 

Less current portion of notes payable

 

 

 

 

387,500

 

 

 

-

 

Notes payable, net of current portion

 

 

 

$1,162,500

 

 

$1,550,000

 

 

 

 

 

 

 

 

 

 

 

 

Notes payable, Cygnet subsidiary:

 

 

 

 

 

 

 

 

 

 

SBA note payable, 30-year term note, 6% interest rate and collateralized with all assets of the Company

 

October 6, 2021

 

 

3,761,376

 

 

 

3,761,376

 

Inventory consignment note, 60 monthly payments, with first payment due June 30, 2022, 3.5% interest rate and no security interest in the assets of the business

 

June 30, 2027

 

 

1,000,290

 

 

 

1,002,221

 

GF Note, 6 annual payments, with first payment due December 31, 2022, 3.5% interest rate and no security interest in the assets of the business

 

November 7, 2026

 

 

685,899

 

 

 

683,968

 

Total

 

 

 

$5,447,565

 

 

$5,447,565

 

 

 

 

 

 

 

 

 

 

 

 

Notes payable, Cygnet subsidiary, current

 

 

 

 

5,447,565

 

 

 

5,447,565

 

 

 

 

 

 

 

 

 

 

 

 

Notes payable, Cygnet subsidiary, net of current

 

 

 

$-

 

 

$-

 

 

 

 

 

 

 

 

 

 

 

 

Notes Payable on Building for sale:

 

 

 

 

 

 

 

 

 

 

Mortgage Loan, 10-year term note, 4.8% interest, collateralized by land and warehouse building

 

September 26, 2032

 

$-

 

 

$2,634,538

 

 

 

 

 

 

 

 

 

 

 

 

Note Payable:

 

 

 

 

 

 

 

 

 

 

Promissory Note, 21-month term note, 10% cash interest and subordinate to the Convertible Notes.  This note was amended as of November 15, 2023, extending the note to June 1, 2026 and adjusted the interest rate to 12%, paid in cash monthly. 

 

June 1, 2026

 

 

560,000

 

 

 

560,000

 

 

 

 

 

 

 

 

 

 

 

 

Notes payable, current

 

 

 

 

140,000

 

 

 

-

 

Discount on notes payable, current

 

 

 

 

-

 

 

 

-

 

Notes payable, current net of discount

 

 

 

$140,000

 

 

$-

 

 

 

 

 

 

 

 

 

 

 

 

Notes payable, long-term 

 

 

 

 

420,000

 

 

 

560,000

 

Discount on notes payable, long-term

 

 

 

 

-

 

 

 

(2,571 )

Notes payable, long-term, net

 

 

 

$420,000

 

 

$557,429

 

 

 

 

 

 

 

 

 

 

 

 

Related Notes Payable:

 

 

 

 

 

 

 

 

 

 

Marshall Loan, 2-year term note, 12% cash interest, 3.5% PIK interest and subordinate to the Convertible Notes. November of 2023 extended to June 1, 2026 and interest was adjusted to 12% cash interest, paid monthly

 

June 1, 2026

 

$500,000

 

 

$500,000

 

 

 

 

 

 

 

 

 

 

 

 

Discount on related party note payable, current

 

 

 

 

125,000

 

 

 

-

 

Notes payable, current, net of discount

 

 

 

$-

 

 

$-

 

 

 

 

 

 

 

 

 

 

 

 

Discount on related party note payable, long term

 

 

 

 

-

 

 

 

-

 

Notes payable, long term, net

 

 

 

$375,000

 

 

$500,000

 

 

 

 

 

 

 

 

 

 

 

 

Total convertible notes payable, acquisition notes payable, notes payable and related party note payable

 

 

 

$8,057,565

 

 

$10,689,532

 

 

 
22

Table of Contents

 

Future payments on notes payable are as follows:

 

For the three months ended September 30:

 

 

 

 

 

 

 

 

 

 

 

 

 

Note Payable

 

 

Related Party Note Payable

 

 

Convertible Notes

 

 

Cygnet Subsidiary Notes Payable

 

 

Total

 

12-months

 

$140,000

 

 

$125,000

 

 

$387,500

 

 

$5,447,565

 

 

$6,100,065

 

1-year

 

 

420,000

 

 

 

375,000

 

 

 

1,162,500

 

 

 

-

 

 

 

1,957,000

 

 

 

 

560,000

 

 

 

500,000

 

 

 

1,550,000

 

 

 

5,447,565

 

 

 

8,057,565

 

Note original discount

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

$560,000

 

 

$500,000

 

 

$1,550,000

 

 

$5,447,565

 

 

$8,057,565

 

 

In June 2022, the Company executed a promissory note with Allan Marshall, the Company’s Chief Executive Officer, in the original principal amount of $1,500,000 (“Marshall Loan”). The promissory note has a 2-year term and bears cash interest at the rate of 8.5% per annum with an additional PIK of 3.5% per annum. The promissory note provides for monthly payments of principal, on an even line 36-month basis, plus cash interest, with a balloon payment of all outstanding principal, cash interest, and PIK interest at maturity. The Company received and deposited the principal amount on July 31, 2022.  On November 15, 2023, the Company executed an amendment to the promissory note with Mr. Marshall, providing for the payment of interest only for 18 months at an interest rate of 12% per annum and thereafter the amortization of the note over a 12 month period, starting in June of 2025.  The principal currently outstanding is $500,000.  In addition to this, the Company issued Mr. Marshall a warrant to purchase up to 18,750 shares of the Company’s common stock for five years at a per share price of $22.00.  The note has been classified as long-term in the consolidated financial statements.  $1,000,000 of the promissory note was used by the investor in the purchase of VitaMedica.

 

On October 19, 2022, Upexi, Inc. (the “Company”) and its indirect wholly owned subsidiary, Upexi 17129 Florida, LLC entered into a loan agreement, promissory note and related agreements with Professional Bank, a Florida state-chartered bank, providing for a mortgage on the Company’s principal office in N. Clearwater, Florida. The Company received $3,000,000 in connection with the transaction. The principal is to be repaid to Professional Bank over a term of ten years. The proceeds of the loan were utilized by the Company to pay down its loan facility with Acorn Capital, LLC in the amount of $2,780,200.  As of March 31, 2023, the Company was not in compliance with the debt service ratio.  The Company received a forbearance agreement from the bank until June 30, 2024 to return to compliance of the debt service ratio of 1.25 to 1, until that time the Company will pay an interest rate of 10% instead of the contractual terms of 4.8% and has paid the original principal and adjusted interest through this report.  The building was sold for $4,300,000 on July 8, 2024.

 

On February 22, 2023, the Company executed a promissory note with an investor, in the original principal amount of $560,000.  On November 15, 2023, the Company executed an amendment to the promissory note with the investor, providing for the payment of interest only for 18 months at 12% per annum and thereafter the amortization of the note over a 12-month period, starting in June of 2025.  The principal currently outstanding is $560,000.  In addition to this, the Company issued the investor a warrant to purchase up to 6,250 shares of the Company’s common stock for five years at a per share price of $22.00.  The note has been classified as long-term in the consolidated financial statements. 

 

On February 22, 2023, the Company executed a promissory note with an investor, in the original principal amount of $2,150,000.   In November of 2023, the Company executed an amendment to the promissory note with the investor, providing for the payment of interest only for 18 months at 12% per annum and thereafter the amortization of the note over a 12-month period, starting in June of 2025. The principal currently outstanding is $2,150,000.  In addition to this, the Company issued the investor a warrant to purchase up to 25,000 shares of the Company’s common stock at a per share price of $22.00.  In addition, $100,000 of the promissory note was used by the investor in the purchase of VitaMedica.  The note has been classified as long-term in the consolidated financial statements.

 

 
23

Table of Contents

 

Note 10. Related Party Transactions

 

In June 2024, Allan Marshall, the Company’s CEO advanced the Company $100,000 to enable the Company to purchase equipment needed for the new warehouse facility.  This advance was paid in July 2024.  No interest or other fees were paid related to this transaction. 

 

On April 1, 2024, the Company entered into a lease agreement with MFA 2510 Merchant LLC, which is owned by our CEO, Allan Marshall.  The lease is for approximately 10,000 square feet of warehouse and office space, located in Odessa, Florida for $20,060 per month on a triple net basis.  The initial term of the lease is five years.   The Company spent $611,768 in leasehold improvements to prepare the facility for product manufacturing, which will be amortized over the five year lease term.  At June 30, 2024 there was $100,004 accrued for the deposit, 3 months’ rent, and 3 months estimated expenses, this was paid in July 2024 and is now kept current.  Product manufacturing was at full capacity and fully moved from the Nevada facility as of August 1, 2024. 

 

On June 13, 2024, the Company entered into a Stock Purchase Agreement (“SPA”) pursuant to which the Company sold one hundred percent (100%) of the issued and outstanding equity (the “Interests”) of its wholly owned subsidiary VitaMedica, Inc. to three investors (the “Buyers”). One of the minority interest buyers is Allan Marshall, the Company’s CEO.  The purchase price for the stock was Six Million Dollars ($6,000,000), subject to certain customary post-closing adjustments.  The proceeds of the transaction will be used for working capital, the reduction of debt and the reduction of other liabilities currently outstanding.

 

In June 2022, the Company entered into a promissory note with a member of management.  The loan was for $1,500,000 and has a two-year term with an interest rate of 8.5% per annum with an additional PIK of 3.5% per annum.   On November 15, 2023, the Company executed an amendment to the promissory note with Mr. Marshall, providing for the payment of interest only for 18 months at an interest rate of 12% per annum and thereafter, the amortization of the note over a 12-month period, starting in June of 2025.  $1,000,000 of the principal was used as part of the VitaMedica purchase price.  The principal outstanding and accrued interest at June 30, 2024 was $500,000 and $169,662, respectively.  The accrued interest was paid in July of 2024.  In addition, the Company issued Mr. Marshall a warrant to purchase up to 18,750 shares of the Company’s common stock for five years at a per share price of $22.00.  The note has been classified as long-term in the consolidated financial statements. 

 

The above related party transactions are not necessarily indicative of the amounts and terms that would have been incurred had comparable transactions been entered into with independent parties.

 

Note 11. Equity Transactions

 

Convertible Preferred Stock

 

The Company has 25,000 shares of Preferred Stock issued and outstanding to Allan Marshall, CEO. The preferred stock is convertible into the Company’s common stock at a ratio of 1.8 shares of preferred stock for a single share of the Company’s common stock at the holder’s option, has preferential liquidation rights and the preferred stock shall vote together with the common stock as a single class on all matters to which shareholders of the Company are entitled to vote at the rate of ten votes per share of preferred stock.

 

Common Stock

 

In September of 2023, the Company issued 4,505 shares of common stock for the purchase of the remaining 45% of Cygnet Online, LLC.  The shares were valued at $162,727 or $36.12 per common share.  These shares were held due to a dispute with the seller. 

 

On January 18, 2024, the Company issued 25,081 shares of common stock as repayment of $500,000 of the Company’s long-term debt. The shares were valued at $500,000 or 19.94 per common share. 

 

On March 18, 2024, the Company issued 5,000 shares of common stock as an incentive-restricted stock grant to certain employees. The shares were valued at $85,000 or $17 per common share.   

 

 
24

Table of Contents

 

The Company effectuated a reverse stock split, at a rate of 20 to 1, effective at 12:01 am ET, October 3, 2024.  The total issued and outstanding shares of the Company’s common stock, post reverse stock split was 1,040,886.  The Depository Trust Company (“DTC”) has requested an additional 202,183 shares of the Company’s common stock to round up, pursuant to the terms of the reverse stock split, the holdings of DTC’s beneficial holders.  These shares were issued on  October 23, 2024 and on October 30, 2024 we were notified that the shares were returned to the Company’s transfer agent. Although the Company did receive the common stock back after issuance, the potential dilution remains a risk, and is the subject of a complaint filed by the Company in the United States District Court for the District of Nevada with the purpose of eliminating any said risk. The Reverse Stock Split did not modify the relative rights or preferences of the Common Stock.   

 

Note 12. Stock Based Compensation

 

The Board of Directors of the Company may from time to time, in its discretion grant to directors, officers, consultants and employees of the Company, non-transferable options to purchase common shares. The options are exercisable for a period of up to 10 years from the date of the grant.

 

The following table reflects the continuity of stock options for the three months ended September 30, 2024 and 2023:

 

A summary of stock option activity for the three months ended September 30, 2024 is as follows:

 

 

 

 

 

Weighted

 

 

Average

 

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Aggregated

 

 

 

Options

 

 

Exercise

 

 

Contractual

 

 

Intrinsic

 

 

 

Outstanding

 

 

Price

 

 

Life (Years)

 

 

Value

 

Outstanding at June 30, 2024

 

 

217,490

 

 

$57.40

 

 

 

5.83

 

 

$0.00

 

Exercised

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Forfeited

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Granted

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Options outstanding at September 30, 2024

 

 

217,490

 

 

$57.40

 

 

 

5.57

 

 

 

0.00

 

Options exercisable at September 30, 2024 (vested)

 

 

197,610

 

 

$58.10

 

 

 

5.59

 

 

$0.00

 

 

A summary of stock option activity for the three months ended September 30, 2023 is as follows:

 

 

 

 

 

Weighted

 

 

Average

 

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Aggregated

 

 

 

Options

 

 

Exercise

 

 

Contractual

 

 

Intrinsic

 

 

 

Outstanding

 

 

Price

 

 

Life (Years)

 

 

Value

 

Outstanding at June 30, 2023

 

 

241,964

 

 

$66.20

 

 

 

6.23

 

 

$1,342,280

 

Exercised

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Forfeited

 

 

(18,900 )

 

$86.80

 

 

 

3.78

 

 

 

-

 

Granted

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Options outstanding at September 30, 2023

 

 

223,064

 

 

$63.40

 

 

 

6.30

 

 

 

372,856

 

Options exercisable at September 30, 2023 (vested)

 

 

204,989

 

 

$60.60

 

 

 

6.49

 

 

$372,856

 

 

Stock-based compensation expense attributable to stock options was $141,298 and $421,887 for the three months ended September 30, 2024, and 2023, respectively.  As of September 30, 2024, there was approximately $123,900 of unrecognized compensation expense related to unvested stock options outstanding, and the weighted average vesting period for those options was approximately 2 years.

 

There were no stock options granted during the three months ended September 30, 2024 or 2023.

 

There were 213,214 shares available for issuance as of September 30, 2024, under the 2019 Plan as amended.

 

 
25

Table of Contents

 

Note 13. Income Taxes

 

The Company computed the year-to-date income tax provision by applying the estimated annual effective tax rate to the year-to-date pre-tax income and adjusted for discrete tax items in the period. For the three months ended September 30, 2024 the Company reserved 100% of the benefit calculated as income tax benefit and calculated a benefit of $472,367 for the three months ended September 30, 2023. 

 

For the three months ended September 30, 2024, the difference between the U.S. statutory rate and the Company’s effective tax rate is due to the full valuation allowance on the Company’s deferred tax assets.  The income tax benefit for the three months ended September 30, 2023, was primarily attributable to federal and state income taxes and nondeductible expenses for an effective tax rate of approximately 25.83%.

 

Future realization of the tax benefits of existing temporary differences and net operating loss carryforwards ultimately depends on the existence of sufficient taxable income within the carryforward period. As of June 30, 2024 the Company performed an evaluation to determine whether a valuation allowance was needed. The Company considered all available evidence, both positive and negative, which included the results of operations for the current and preceding years. The Company also considered whether there was any currently available information about future years. The Company determined that it is more likely than not that the Company will have future taxable income. The Company used $2,506,514 of the federal net operating loss carryover during the year ended June 30, 2022, however during the years ended June 30, 2024 and June 30, 2023 the federal net operating loss increased significantly and management recorded a valuation reserve of $6,100,000.  As of September 30, 2024 the Company had a valuation reserve of approximately $6,535,000.

 

We file federal and state income tax returns in jurisdictions with varying statutes of limitations. Income tax returns generally remain subject to examination by federal and most state tax authorities. We are not currently under examination in any federal or state jurisdiction.

 

Note 14. Risks and Uncertainties

 

There is substantial uncertainty and different interpretations among federal, state and local regulatory agencies, legislators, academics and businesses as to the scope of operation of Farm Bill-compliant hemp programs relative to the emerging regulation of cannabinoids. These different opinions include, but are not limited to, the regulation of cannabinoids by the U.S. Drug Enforcement Administration, or DEA, and/or the FDA and the extent to which manufacturers of products containing Farm Bill-compliant cultivators and processors may engage in interstate commerce. The uncertainties cannot be resolved without further federal, and perhaps even state-level, legislation, regulation or a definitive judicial interpretation of existing legislation and rules. If these uncertainties continue, they may have an adverse effect upon the introduction of our products in different markets.

 

 
26

Table of Contents

 

Note 15. Discontinued Operations – Sale of Interactive Offers

 

On August 31, 2023, the Company sold Interactive offers to Amplifyir Inc. The purchase price is $1,250,000 with a provision to adjust the final purchase price based on the business being transferred to Amplifyer Inc. with a net zero working capital. In addition, the Buyer is obligated to pay the Company two-and one-half percent (2.5%) of certain advertising revenues of Interactive for a two-year period post-closing. Accordingly, the results of the business were classified as discontinued operations in our statements of operations and excluded from both continuing operations and segment results for all periods presented.

 

Summary of discontinued operations:

 

 

 

Three months

ended

September 30,

2023

 

Discontinued Operations

 

 

 

Revenue

 

$158,147

 

Cost of sales

 

$11,982

 

Sales, general and administrative expenses

 

$339,205

 

Depreciation and amortization

 

$-

 

Income (loss) from discontinued operations

 

$(193,040 )

Accounts receivable net of allowance for doubtful accounts

 

$-

 

Fixed assets, net of accumulated depreciation

 

$-

 

Total assets

 

$-

 

Total liabilities

 

$-

 

 

Note 16. Discontinued Operations – Sale of VitaMedica

 

On June 13, 2024, the Company sold VitaMedica, Inc. to three investors and had an effective day of June 1, 2024.  One of the minority interest investors is Allan Marshall, the Company’s Chief Executive Officer. The purchase price for the stock was $6,000,000, subject to certain customary post-closing adjustments. In addition, the Buyers are obligated to pay the Company for services provided according to the Transition Services Agreement.  Accordingly, the results of the business were classified as discontinued operations in our statements of operations and excluded from both continuing operations and segment results for all periods presented.  Discontinued operations of VitaMedica included in the consolidated financial statements for the three months ended September 30, 2023 are as follows:

 

Summary of discontinued operations:

 

 

 

Three months

ended

September 30,

2023

 

Discontinued Operations

 

 

 

Revenue

 

$1,980,396

 

Cost of sales

 

$365,384

 

Sales, general and administrative expenses

 

$1,412,774

 

Depreciation and amortization

 

$132,558

 

Other expenses

 

$274

 

Income (loss) from discontinued operations

 

$69,406

 

Accounts receivable net of allowance for doubtful accounts

 

$306,550

 

Fixed assets, net of accumulated depreciation

 

$77,006

 

Total assets

 

$4,935,215

 

Total liabilities

 

$507,807

 

 

 
27

Table of Contents

 

Note 17. Discontinued Operations – Sale of E-Core

 

E-Core, Technology Inc. and its subsidiaries

 

On August 1, 2024, the Company closed a sale transaction in which, effective as of June 30, 2024, it sold 100% of the outstanding stock of its wholly owned subsidiary E-Core Technology, Inc., a Florida corporation (d/b/a New England Technology, Inc.) (“E-core”), to E-Core Holdings, LLC, a Florida limited liability company (the “Buyer”) pursuant to the terms of an Agreement to Unwind Securities Purchase Agreement dated July 31, 2024 (the “Agreement”).  The principals of the Buyer are the three individuals from whom the Company acquired E-core in October 2022.  The purchase price in the transaction was $2,000,000 paid by the Buyer to the Company at closing.  In addition, in connection with the closing of the transaction (i) the Company was released as a guarantor from E-core’s commercial loan facility, and (ii) all subordinated promissory notes issued by the Company in connection with the Company’s initial acquisition of E-core were cancelled and any outstanding principal and interest thereunder was deemed paid in full.  The Agreement contains standard representations and warranties, conditions to closing, and covenants, for a transaction of this nature.

 

Accordingly, the results of the business were classified as discontinued operations in our statements of operations and excluded from both continuing operations and segment results for all periods presented. Discontinued operations of E-core included in the consolidated financial statements for the three months ended September 30, 2023 are as follows:

 

Summary of discontinued operations:

 

 

 

Three months

ended

September 30,

2023

 

Discontinued Operations

 

 

 

Revenue

 

$17,092,372

 

Cost of sales

 

$15,425,799

 

Sales, general and administrative expenses

 

$1,005,697

 

Depreciation and amortization

 

$403,875

 

Other expenses

 

$32,650

 

Income from discontinued operations

 

$224,351

 

Accounts receivable net of allowance for doubtful accounts

 

$6,683,194

 

Fixed assets, net of accumulated depreciation

 

$-

 

Total assets

 

$21,924,064

 

Total liabilities

 

$2,701,212

 

 

 
28

Table of Contents

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

General Overview

 

As used in this current report and unless otherwise indicated, the terms “we”, “us” and “our” mean Upexi, Inc.

 

The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The consolidated financial statements include the accounts of all subsidiaries in which the Company holds a controlling financial interest as of the financial statement date.

 

For the three months ended September 30, 2024, the consolidated financial statements of Upexi, Inc. include all of the subsidiary accounts included in the consolidated financial statements for the three months ended September 30, 2023. 

 

Interactive Offers, LLC a Delaware limited liability corporation; VitaMedica, a Nevada corporation; and E-Core Technology, Inc. d/b/a New England Technology, Inc. have been classified as discontinued operations for the three months ended September 30, 2023 and the assets and liabilities have been classified as current assets, and liabilities of discontinued operations and assets held for sale on the balance sheets for September 30, 2023.  There were no operations, assets or liabilities related to these discontinued operations for the three months ended September 30, 2024. 

 

All intercompany accounts and transactions have been eliminated as a result of the consolidation.

 

Operating Segments

 

The Company’s financial reporting is organized into a single segment that includes production, sales and distribution of branded products, following the sale of E-Core, Technology Inc. and its subsidiaries. Other sources of revenue and related costs are aggregated and viewed by management as immaterial or have similar economic characteristics, products, production, distribution processes and regulatory environment as the other product sales or directly support the Company’s single segment.

 

Results of Operations

 

The following summary of the Company’s operations should be read in conjunction with its unaudited condensed consolidated financial statements for the three months ended September 30, 2024 and 2023, which are included herein.

 

Three Months Ended September 30, 2024 Compared to Three Months Ended September 30, 2023

 

 

 

September 30,

 

 

 

 

 

 

2024

 

 

2023

 

 

Change

 

Revenue

 

$4,356,515

 

 

$8,274,690

 

 

$(3,918,175 )

Cost of revenue

 

$1,426,447

 

 

$2,845,201

 

 

$(1,418,754 )

Sales and marketing expenses

 

$1,041,425

 

 

$1,816,702

 

 

$(775,277 )

Distribution costs

 

$1,455,725

 

 

$2,131,892

 

 

$(676,167 )

General and administrative expenses

 

$1,367,690

 

 

$1,578,350

 

 

$(210,660 )

Other operating expenses

 

$400,393

 

 

$1,358,358

 

 

$(957,965 )

Other expenses (income)

 

$290,412

 

 

$853,283

 

 

$(562,871 )

Gain on the sale of business

 

$-

 

 

$380,624

 

 

$(380,624 )

Discontinued operations

 

$-

 

 

$100,717

 

 

$(100,717 )

Net (loss) income from continuing operations

 

$(1,625,577 )

 

$(1,355,388 )

 

$(270,189 )

 

Revenues declined by $3,918,175 or 47% to $4,356,515 compared with revenue of $8,274,690 in the same period last year. Approximately $3,170,000 of the decline was related to the discontinued recommerce business in other subsidiaries after the sale of E-core.  Management has augmented the overall strategy of the Company to focus on product sales, including the development, production and distribution of branded products.   In addition, sales were affected by the manufacturing consolidation to Florida, which was completed by August 1, 2024, with manufacturing returning to full production. 

 

Cost of revenue decreased by 1,418,754 or 50% compared with the same period last year.  The cost of revenue decrease is directly related to the sales declines described above.   Gross margin remained the same between the two periods with less than a 2% change. 

 

Sales and marketing expenses decreased by $775,277 or 43% compared with the same period last year.  The decrease in sales and marketing expenses was primarily related to the reduction of unnecessary agency expenses and a focused strategy on our core products.   

 

Distribution costs decreased by $676,167 or 32% compared with the same period last year.  The decrease in distribution costs was primarily related to the overall decline in the recommerce revenue.  Management will continue to reduce overall distribution costs with the consolidation of products and facilities.  

 

 
29

Table of Contents

 

General and administrative expenses decreased by $210,660 or 13% compared with the same period last year.  Since the consolidation to Florida and other changes in the business, management has actively been reducing general and administrative costs.  Management expects that general and administrative expenses to continue to decline, with the most significant declines being realized in periods ending after December 31, 2024.  

 

Other operating expenses decreased by $957,965 or 71% compared with the same period last year. The decrease in other operating expenses was primarily related to the change in amortization of acquired intangible assets and the decreased amortization of stock-based compensation. 

 

Other expenses, which is primarily interest decreased by $562,871 or 66% compared with the same period last year. The decrease in interest expense was primarily related to the elimination of the acquisition debt for E-core and the elimination of debt with the sale of VitaMedica in the prior year.  

 

A gain of $380,624 was recognized on the sale of Interactive offers and there was net income of $100,717 from discontinued operations. 

 

The Company had a net loss of $1,625,577 for the three months ended September 30, 2024 compared to a loss of $1,333,388 for the three months ended September 30, 2023.  The increase in the net loss is primarily related to the above-mentioned changes.

 

Liquidity and Capital Resources

 

Working Capital

 

 

 

As of

September 30,

2024

 

 

As of

June 30,

2024

 

Current assets

 

$

6,790,280

 

 

$

11,419,918

 

Current liabilities

 

 

9,771,401

 

 

 

12,655,152

 

Working capital

 

$

(2,981,121

)

 

$

(1,235,234

)

 

Cash Flows

 

 

 

Three Months Ended September 30,

 

 

 

2024

 

 

2023

 

Cash flows used by operating activities – continuing operations

 

$

(1,974,592

)

 

$

(2,073,232

)

Cash flows used by investing activities – continuing operations

 

 

5,838,106

 

 

 

145,324

 

Cash flows (used in) provided by financing activities – continuing operations

 

 

(2,734,538

)

 

 

(325,942

)

 

 

 

 

 

 

 

 

 

Cash flows used in operating activities – discontinued operations

 

 

-

 

 

 

(1,718,972

)

Cash flows used by investing activities – discontinued operations

 

 

-

 

 

 

-

 

Cash flows provided (used by) financing activities – discontinued operations

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Net increase (decrease) in cash during the period

 

$

1,128,976

 

 

$

(3,972,822

)

 

On September 30, 2024, the Company had cash of $1,790,391, an increase of $1,128,976 from June 30, 2024.  The increase in cash was primarily the sale of the building and the collection of the purchase price for E-core.  

 

Net cash from operating activities benefited from non-cash expenses of $402,964, which was offset by an approximate $400,000 increase in accounts receivable and inventory and approximately $500,000 in the reduction of several liabilities.   The negative cash flow from operations was anticipated by management as the Company augmented the overall strategy of the Company to focus on product sales, including the development, production and distribution of branded products.  

 

 
30

Table of Contents

 

Net cash provided by investing activities for the three months ended September 30, 2024 and 2023 was $5,838,106 and $145,324, respectively.  For the three months ended September 30, 2024 the primary cash provided was the sale of the building and the collection of the purchase price for E-core.  For the three months ended September 30, 2023, $940,000 was provided by the sale of Interactive offers and $500,000 and $294,676 was used for the purchase of the remaining equity of Cygnet and the acquisition of property and equipment, respectively.    

 

Net cash flows used in financing activities for the three months ended September 30, 2024 was $2,734,538 compared to $325,942 used during the three months ended September 30, 2023.  $2,634,538 used was the repayment of the loan collateralized by the building and the $100,000 advance to the Company by Allan Marshall, the CEO, was repaid during the three months ended September 30, 2024.  During the three months ended September 30, 2023 the use of cash was for the scheduled repayment of debts.   

 

We estimate that we will have sufficient working capital to fund our operations over the twelve months following the date of the issuance of these condensed consolidated financial statements and meet all of our debt obligations.

 

Off-Balance Sheet Arrangements

 

There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not applicable.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Under the supervision and with the participation of our senior management, including our chief executive officer and chief financial officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of September 30, 2023 (the “Evaluation Date”). Based on this evaluation, our principal executive officer and principal financial and accounting officer concluded as of the Evaluation Date that our disclosure controls and procedures were not effective such that the information relating to us required to be disclosed in our Securities and Exchange Commission (“SEC”) reports (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate to allow timely decisions regarding required disclosure. This conclusion is based on findings that constituted material weaknesses. A material weakness is a deficiency, or a combination of control deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s interim financial statements will not be prevented or detected on a timely basis.

 

 
31

Table of Contents

 

In performing the above-referenced assessment, our management identified the following material weaknesses:

 

 

(i)

inadequate segregation of duties consistent with control objectives; and

 

 

 

 

(ii)

lack of multiple levels of supervision and review.

 

We believe the weaknesses and their related risks are not uncommon in a company of our size because of the limitations in the size and number of staff. Due to our size and nature, segregation of all conflicting duties has not always been possible and may not be economically feasible.  However, we plan to take steps to enhance and improve the design of our internal control over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the appointment of additional qualified personnel to address inadequate segregation of duties and implement modifications to our financial controls to address such inadequacies, by the end of our 2024 fiscal year as resources allow.

 

We are currently reviewing our disclosure controls and procedures related to these material weaknesses and expect to implement changes in the current fiscal year, including identifying specific areas within our governance, accounting and financial reporting processes to add adequate resources to potentially mitigate these material weaknesses.

 

Our management will continue to monitor and evaluate the effectiveness of our internal controls and procedures and our internal controls over financial reporting on an ongoing basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.

 

Because of its inherent limitations, internal controls over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

 

Changes in Internal Control Over Financial Reporting

 

There have been no changes in our internal controls over financial reporting (as defined in Rules 12a-15(f) and 15d-15(f) under Exchange Act) that occurred during the quarter ended September 30, 2024, that have materially or are reasonably likely to materially affect, our internal controls over financial reporting. The Company has added significant qualified resources to ensure proper segregation of duties and proper review of the financial reporting policies and procedures.

 

 
32

Table of Contents

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

From time to time, the Company may become involved in litigation relating to claims arising out of its operations in the normal course of business. The Company is not involved in any pending legal proceeding or litigation, and, to the best of its knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of its properties is subject, which would reasonably be likely to have a material adverse effect on the Company.

 

Item 1A. Risk Factors

 

As a “smaller reporting company”, the Company is not required to provide the information required by this Item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

All of the securities issued by the Company were issued pursuant to the exemption for transactions by an issuer not involved in any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder and corresponding state securities laws. For more information regarding securities issued, see the Liquidity and Capital Resources section to our Unaudited Condensed Consolidated Financial Statements included herein.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

 
33

Table of Contents

 

Item 6. Exhibits

 

Exhibit

Number

 

Description

31.1*

 

Certification of Principal Executive Officer, pursuant to Rule 13a-14a and 15-d-14a of the Securities Exchange Act of 1934

31.2*

Certification of Principal Financial Officer, pursuant to Rule 13a-14a and 15-d-14a of the Securities Exchange Act of 1934

32.1*

 

Certification of Principal Executive Officer, pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2*

Certification of Principal Financial Officer, pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101**

 

Interactive Data File

101.INS

 

Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

 

Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

_________________

*

Filed herewith.

**

Furnished herewith.

 

 
34

Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

UPEXI, INC.

 

 

 

 

Dated: December 19, 2024

 

/s/ Allan Marshall

 

 

 

Allan Marshall

 

 

 

President, Chief Executive Officer, and Director

 

 

 

(Principal Executive Officer)

 

 

Dated: December 19, 2024

 

/s/ Andrew J. Norstrud

 

 

 

Andrew J. Norstrud

 

 

 

Chief Financial Officer

 

 

 

(Principal Financial Officer and Principal Accounting Officer)

 

 

 
35